The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter is used routinely to guide chemotherapeutic treatment decisions, especially in glioblastoma (GBM) (e.g., grade IV astrocytoma), which is the most common type of DG. The gene discussed is MGMT; the disease is astrocytoma (excluding glioblastoma).